New drug combo aims to boost stem cell transplant success for tough blood cancers
NCT ID NCT07044544
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether adding two drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant can safely help control high-risk myeloid cancers like acute myeloid leukemia. About 20 adults aged 18-75 with a matched donor will receive the drugs alongside the transplant. The main goal is to find a safe dose and watch for serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Decitabine and Venetoclax
What this could lead to
If this works, it could lead to a safer and more effective way to control high-risk myeloid cancers using a stem cell transplant.
What could go wrong
This is a very early phase 1 trial with only 20 people, so it's mainly checking safety. The added drugs may cause serious side effects, and it's too soon to know if they will improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact